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Abstract 
Purpose : To evaluate the associations between anti-VEGF therapy and central choroidal 
thickness (CCT), choroidal vascular density (CVD) and choroidal vascular volume (CVV), in 
patients with Diabetic Macular Edema (DME) using Swept Source OCT (SS-OCT), and to 
correlate these findings with treatment visual outcomes. 
Methods : Prospective longitudinal study, including consecutive patients with treatment-
naive DME. All patients received monthly ranibizumab intravitreal injections for 3 months 
(loading dose) followed by a treat-and-extend regimen during 12 months. BCVA and 3D 
horizontal volume macular SS-OCT scans (Topcon®DRI OCT-1 Atlantis) were obtained 
before 1stinjection (M0), 1 month after loading dose (M3), and at 6 (M6) and 12 months (M12) 
after 1stinjection. CCT was calculated as the mean central 1mm value of ETDRS 
grid.Enface SS-OCT images of choroidal vasculature were binarized to calculate CVD and 
CVV. CVD was defined as the percent area occupied by choroidal vessels in macular region 
(6-mm diameter circle centred on fovea) and CVV was calculated by multiplying the average 
CVD by the macular area and choroidal thickness. Treatment visual outcome was defined 
as BCVA improvement after M3 and categorized into 2 groups:Good Responders(≥5 letters) 
and Poor Responders(<5 letters). 
Results : Twenty-three naïve DME eyes were included. After the loading dose of 
ranibizumab (M3), 17 eyes (73.9%) were good responders and 7 (30.4%) poor responders. 
At baseline, good responders showed a thicker choroid compared with poor responders 
(199.7±79.6μm vs182.5±60.4μm;p=0.134). Macular CVD and CVV were also significantly 
higher in good responders (CVD=0.26±0.06 vs0.21±0.03; 
CVV=1.73±0.95 vs1.28±0.48;p=0.151). After treatment, two distinct behaviors were 
observed: a significant decrease of CCT in good responders (-11.3%;p=0.014) and an 
increase in poor responders that did not reach statistical significance (+8.5%;p=0.576). CVD 
and CVV showed analogous changes with significant reductions in good responders (CVV= 
-13.8%;p=0.008) and increases in poor responders (CVD=+16.2%;p=0.006; 
CVV=+34.1%;p=0.134). CVD at baseline identified well the good responders to anti-VEGF 
treatment (ROC AUC=0.74;p=0.030). 
Conclusions : Choroidal indices such as CVD and CVV, measured at baseline, discriminate 
the good and poor responders to anti-VEGF therapy in DME patients, and may be robust 
predictors of treatment response. 
 
